Prati
Miodrag Dragoj
Miodrag Dragoj
Research Associate, Institute for Biological Research "Sinisa Stankovic", University of Belgrade
Potvrđena adresa e-pošte na ibiss.bg.ac.rs - Početna stranica
Naslov
Citirano
Citirano
Godina
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma
M Dragoj, Z Milosevic, J Bankovic, N Tanic, M Pesic, T Stankovic
Cellular oncology 40, 47-62, 2017
402017
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies
T Stanković, T Ranđelović, M Dragoj, SS Burić, L Fernández, I Ochoa, ...
Drug Resistance Updates 55, 100753, 2021
352021
Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives
T Stanković, B Dankó, A Martins, M Dragoj, S Stojković, A Isaković, ...
Cancer chemotherapy and pharmacology 76, 555-565, 2015
292015
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma
Z Milošević, J Banković, J Dinić, C Tsimplouli, E Sereti, M Dragoj, ...
Cellular oncology 41, 409-426, 2018
282018
Chemo-protective and regenerative effects of diarylheptanoids from the bark of black alder (Alnus glutinosa) in human normal keratinocytes
J Dinić, T Ranđelović, T Stanković, M Dragoj, A Isaković, M Novaković, ...
Fitoterapia 105, 169-176, 2015
262015
Novel TrxR1 inhibitors show potential for glioma treatment by suppressing the invasion and sensitizing glioma cells to chemotherapy
M Jovanović, M Dragoj, D Zhukovsky, D Dar’in, M Krasavin, M Pešić, ...
Frontiers in Molecular Biosciences 7, 586146, 2020
202020
Association of overexpressed MYC gene with altered PHACTR3 and E2F4 genes contributes to non-small cell lung carcinoma pathogenesis
M Dragoj, J Bankovic, A Podolski-Renic, SS Buric, M Pesic, N Tanic, ...
Journal of Medical Biochemistry 38 (2), 188, 2019
182019
development and validation of a long-term 3D glioblastoma cell culture in alginate microfibers as a novel bio-mimicking model system for preclinical drug testing
M Dragoj, J Stojkovska, T Stanković, J Dinić, A Podolski-Renić, ...
Brain Sciences 11 (8), 1025, 2021
162021
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors
M Dragoj, J Bankovic, E Sereti, SJ Stojanov, K Dimas, M Pesic, ...
Investigational New Drugs 35 (6), 718-732, 2017
142017
Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients’ outcome
M Dragoj, Z Milosevic, J Bankovic, J Dinic, M Pesic, N Tanic, T Stankovic
Tumor Biology 36, 8773-8780, 2015
142015
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells
A Kostić, S Jovanović Stojanov, A Podolski-Renić, M Nešović, M Dragoj, ...
Brain Sciences 11 (7), 884, 2021
112021
Decreased TSPAN14 expression contributes to NSCLC progression
M Jovanović, T Stanković, S Stojković Burić, J Banković, J Dinić, M Ljujić, ...
Life 12 (9), 1291, 2022
62022
Nano-motion analysis for rapid and label free assessing of cancer cell sensitivity to chemotherapeutics
P Stupar, A Podolski-Renić, MI Villalba, M Dragoj, S Jovanović Stojanov, ...
Medicina 57 (5), 446, 2021
42021
On optimal temozolomide scheduling for slowly growing glioblastomas
B Segura-Collar, J Jiménez-Sánchez, R Gargini, M Dragoj, ...
Neuro-Oncology Advances 4 (1), vdac155, 2022
32022
Chemosensitivity and survival of non-small cell lung carcinoma patients receiving neoadjuvant therapy depend on the expression of multidrug efflux transporters
S Tijana, S Jelena, D Miodrag, M Zorka, M Zorica, M Vedrana, ST Vesna, ...
Journal of Molecular and Clinical Medicine 2 (4), 129-135, 2019
22019
Alpha-1 antitrypsin expression is upregulated in multidrug-resistant cancer cells
A Divac Rankov, S Jovanović Stojanov, M Dragoj, M Ljujić
Histochemistry and Cell Biology 159 (5), 431-437, 2023
12023
Immunofluorescence-Based Assay for High-Throughput Analysis of Multidrug Resistance Markers in Non-Small Cell Lung Carcinoma Patient-Derived Cells
J Dinić, A Podolski-Renić, M Dragoj, S Jovanović Stojanov, A Stepanović, ...
Diagnostics 13 (24), 3617, 2023
2023
34P Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
J Dinić, A Podolski-Renic, M Dragoj, SJ Stojanov, A Stepanović, E Lupšić, ...
ESMO Open 8 (1), 2023
2023
High-throughput screening of multidrug-resistance markers in non-small cell lung carcinoma patient-derived cells–contribution to personalized treatment
SJ Stojanov, A Podolski-Renić, J Dinić, M Dragoj, M Jovanović, ...
ONCOLOGY INSIGHTS 616, 2023
2023
69P Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
SJ Stojanov, A Podolski-Renic, J Dinić, M Dragoj, M Jovanović, ...
ESMO Open 8 (1), 2023
2023
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20